|
| Authors | Year | Gb dose | Type of study | Comparator | Concomitant medications | Outcome measure | Findings |
|
| Attention-deficit and hyperactivity disorder (ADHD) |
|
| Salehi et al. [35] | 2010 | 80 mg/day if weight <30 kg; otherwise 120 mg/day | Randomized,
6 week | Methylphenidate 20 mg/day if weight <30 kg; otherwise 30 mg/day | None | Parent and Teacher ADHD Rating Scale-IV | Significant improvement with methylphenidate |
|
| Autism |
|
| Hasanzadeh et al. [34] | 2012 | 80 mg/day if weight <30 kg; otherwise 120 mg/day | Randomized placebo controlled, 10 weeks | Placebo | Risperidone 2-3 mg/day according to weight | ABC-C | No difference |
|
| Cocaine addiction |
|
| Kampman et al. [36] | 2003 | 240 mg/day | Randomized placebo controlled, 10 weeks | Piracetam 4.8 g/day or placebo | None | Urine toxicology screen or self-report relapse | No significant difference of both piracetam or Gb to placebo |
|
| Dementia |
|
| Herrschaft et al. [42] | 2012 | 240 mg/day | Randomized placebo controlled, 24 weeks | Placebo | Antihypertensive, antithrombotic drug | SKT, NPI, AD CGI, ADL, QOL | Significant improvement with active treatment |
| Ihl et al. [43] | 2011 | 240 mg/day | Randomized placebo controlled, 24 weeks | Placebo | Antihypertensive, antithrombotic drug | SKT, NPI, AD CGI, ADL, QOL | Significant improvement with active treatment |
| Napryeyenko and Borzenko [44] | 2007 | 240 mg/day | Randomized placebo controlled, 22 weeks | Placebo | Antihypertensive, antithrombotic drug | SKT, NPI, ADL | Significant improvement |
| Schneider et al. [45] | 2005 | 120 or 240 mg/day | Randomized placebo controlled, 26 weeks | Placebo | | ADAS-cog | Improvement |
| van Dongen et al. [46] | 2003 | 160 or 240 mg/day | Randomized placebo controlled, 24 weeks | Placebo | | SKT, CGI, NAI-NAA | No differences between Gb and placebo |
| Le Bars et al. [47] | 1997 | 120 mg/day | Randomized placebo controlled, 52 weeks | Placebo | | ADAS-Cog, GERRI, CGIC | Significant improvement in ADAS-cog and GERRI |
| Maurer et al. [48] | 1997 | 240 mg/day | Randomized placebo controlled, 12 weeks | Placebo | | SKT, ADAS-cog, CGI | Significant improvement in SKT |
| Kanowski et al. [49] | 1996 | 240 mg/day | Randomized placebo controlled, 24 weeks | Placebo | | SKT, CGI, NBA | Significant improvement |
| Yancheva et al. [50] | 2009 | 240 mg/day | Randomized versus donepezil or Gb and donepezil, 22 weeks | Donepezil 10 mg/day | Antihypertensive, antithrombotic drug | SKT, NPI, ADL | No significant differences between treatments |
| Mazza et al. [51] | 2006 | 160 mg/day | Randomized placebo controlled, double blind,
24 weeks | Donepezil 10 mg/day | Benzodiazepines or antipsychotics at low dosage | MMSE, SKT, CGI | Significant improvement compared to placebo, no differences with donepezil |
|
| Generalized anxiety disorder (GAD) |
|
| Woelk et al. [37] | 2007 | Two groups: low dose 240 mg/day; high dose 480 mg/day | Randomized placebo controlled, 4 weeks | Placebo | None | HAMA scale | Significant improvement compared to placebo, dose-response relationship |
|
| Schizophrenia |
|
| Doruk et al. [39] | 2008 | 120 mg/day | Randomized placebo controlled, 12 weeks | Placebo | Clozapine 350–500 mg/day | SANS, SAPS, BPRS | Significant improvement in negative symptoms with Gb |
| Zhang et al. [40] | 2001 | 360 mg/day | Randomized placebo controlled, 12 weeks | Placebo | Haloperidol 0.25 mg/kg/day | SANS, SAPS, BPRS | Significant improvement in positive symptoms and negative symptoms with Gb |
| Atmaca et al. [41] | 2005 | 300 mg/day | Randomized olanzapine and EGb versus olanzapine alone,
8 weeks | Placebo | Olanzapine 5–20 mg/day | SANS, SAPS | Significant improvement in positive symptoms with Gb |
|
| Tardive dyskinesia |
|
| Zhang et al. [38] | 2011 | 240 mg/day | Randomized placebo controlled, 12 weeks | Placebo | Antipsychotic or cholinergic agents | AIMS and SANS and SAPS | Significant change in AIMS score. No effect of Gb on psychopathological symptoms |
|
